Keep pulling the thread on Yaw Pharma.
In 2025, Pfizer returned $9.8 billion to shareholders through its quarterly dividend.
The FDA recently approved PADCEF in combination with PEMBRO for patients with muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy.
Pfizer is targeting the first potential approvals for its obesity portfolio to begin in 2028.
For the full year 2025, Pfizer recorded revenues of $62.6 billion, a 2% operational decline from the previous year.
For the full year 2025, Pfizer reported a diluted EPS of $1.36 and an adjusted diluted EPS of $3.22.
In Q4 2025, Pfizer recorded revenues of $17.6 billion, a 3% operational decrease year-over-year.
In Q4 2025, Pfizer reported a GAAP diluted loss per share of $0.29 and an adjusted diluted EPS of $0.66.
In Q4 2025, Pfizer recorded approximately $4.4 billion in non-cash intangible asset impairments related to development and in-line products.
Pfizer is on track to deliver the majority of its targeted $7.2 billion in total net cost savings from productivity programs by the end of 2026.
Pfizer projects its full-year 2026 revenues to be in the range of $59.5 billion to $62.5 billion.
Pfizer projects its full-year 2026 adjusted diluted EPS to be in the range of $2.80 to $3.00 per share.
In 2026, Pfizer expects key Phase 3 readouts for Albrexio in relapsed/refractory multiple myeloma and for its Lyme disease vaccine candidate.